Protocol Ledger

NCT03699202 · Phase II · TERMINATED

Anti-RSV Study in Chinese Patients (ASCENT)

Interventional Phase II clinical trial protocol NCT03699202 sponsored by Shanghai Ark Biopharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-28 Enrollment: 1 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03699202
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03699202
Protocol FieldVerified Registry Value
NCT IdentifierNCT03699202
Consolidated Lead SponsorShanghai Ark Biopharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment1 participants (ACTUAL)
Registered Start Date2019-03-28
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03699202
Hospital Research SiteLocationSite Profile
The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->
Nanjing First HospitalNanjing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI